Board of DirectorsPrint this Page


Harris Kaplan is Chief Executive Officer of Healogix, which he founded in 2004.



Andrew Hall is founder of Black Tulip Group, an advisory and investment firm focused on the marketing, media and information services industries. Prior to forming Black Tulip, Mr. Hall was Executive Vice President of WPP Group plc, the world’s largest advertising & marketing services company where he worked between 1993 and 2000. Over this period, WPP enjoyed great success as a consolidator of the industry growing from around $2b in revenue to around $7b and being amongst the very best performing companies in the FTSE 100. Prior to joining WPP,  Mr. Hall worked in the UK with both Arthur Andersen & Co. and the Corporate Advisory Services Group of Ernst & Young. Mr. Hall holds an MBA from the London Business School, a BA in Economics & Finance from the University of Newcastle upon Tyne and an ACA qualification from the Institute of Chartered Accountants in England & Wales.


Thomas A. Moore is the CEO of Advaxis, a biotechnology company developing novel Listeria-based therapeutic cancer vaccines. Moore, 55, who has served on the Advaxis Board of Directors since September 2006 brings more than 25 years of experience in healthcare and general management. Mr. Moore is currently a board member of Alteon, Inc., a publicly traded developer of pharmaceuticals for the treatment of diabetes and age-related diseases, El Dorado Inc., a targeted marketer to unassimilated Hispanics, Medmeme, which measures medical education effectiveness, and Opt-e-scrip, Inc., which markets a clinical system to compare multiple drugs in the same patient. He also serves as Chairman of Mayan Pigments, Inc., which has developed and patented Mayan pigment technology. Previously, from June 2002 to June 2004 Mr. Moore was President and Chief Executive Officer of Biopure Corporation, a developer of oxygen therapeutics that are intravenously administered to deliver oxygen to the body’s tissues. From 1996 to November 2000 he was President and Chief Executive Officer of Nelson Communications.

Previously, Mr. Moore had a 23-year career with the Procter & Gamble Company in multiple managerial positions, including President of Health Care Products where he was responsible for prescription and over-the-counter medications worldwide, and Group Vice President of the Procter & Gamble Company.


Diana (Didi) Scott has spent the majority of her career at Merck &Co. Inc. in a diversity of marketing roles, including marketing planning, marketing research, and marketing promotion. Her experience in the pharmaceutical industry spans 28+ years as a Vice President in both US and Global (Europe, Latin America, Asia Pacific) operations.

In addition to her experience in “big pharma”, in 1992 Ms. Scott was part of a small group of Merck executives appointed to design and implement a new joint venture pharmaceutical company, Astra Merck, focused on the marketing and sales of Astra-developed products. In addition to leading a variety of franchise teams responsible for the marketing and sales of Gastrointestinal, Cardiovascular and Infectious Disease products, Ms. Scott specializes in the design and implementation of new marketing support organizations. Ms. Scott has also put her marketing expertise to work in the not-for-profit sector, most recently as President of the North Penn Regional Council of the Arts, a group responsible for building and launching a new performing arts center in Lansdale, PA. Ms. Scott has an MBA in Marketing from Temple University and a BA in Fine Arts from Colgate University.


Tim Edbrooke is the President of Healogix.



Bart has 30 years of marketing research experience as a consultant, senior executive and leader. He has advised pharmaceutical and biotechnology companies for over 25 years.  He has worked to help clients reduce their decision making risk related to early stage new product development , forecasting, product positioning and brand communication strategy. He is expert in all aspects of primary research: qualitative and quantitative; domestic and internationally.  He has worked in almost every therapeutic category and with most of the leading pharmaceutical and biotechnology companies.  He has been a frequent presenter and workshop leader at PMRG, PBIRG and Ephmra conferences since 1995.

Bart is the retired Group President and Chief Operating Officer of GfK Healthcare and of V2 and was previously President of Migliara/Kaplan.